<DOC>
	<DOC>NCT00293176</DOC>
	<brief_summary>To investigate the efficacy and safety of donepezil in individuals with mild cognitive impairment on measures of cognition, global function and behavior.</brief_summary>
	<brief_title>The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)</brief_title>
	<detailed_description />
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Memory Disorders</mesh_term>
	<mesh_term>Amnesia</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Memory complaint Mini Mental Status Exam (MMSE) score 2428 inclusive General cognition and function performance sufficiently preserved such that a diagnosis of Alzheimer's disease (AD) cannot be made Generally healthy and ambulatory Sufficiently fluent in English Diagnosis of probable or possible AD Neurological disorders History of malignant cancers Previously have taken donepezil or other acetylcholinesterase (ChE) inhibitors for more than 1 month or in the past 3 months prior to study entry</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Cognitive impairment</keyword>
	<keyword>Memory Loss</keyword>
</DOC>